By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro ...
The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets ...
AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...
Daily Mail on MSN
Covid vaccine victim who lost the use of her hands was 'not disabled enough' for compensation
Marie-Claire Hoyle volunteered to take part in the AstraZeneca Covid-19 vaccine trial in 2020 but just two weeks after her ...
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...
Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...
AstraZeneca (AZN) inks up to $1.5B AI drug discovery deal with insitro to target MASH and cardiomyopathies. Read more here.
BioSpectrum India on MSN
AstraZeneca India opens new Mumbai office for next phase of growth through innovation
Focused on expanding access to innovation, deepening partnerships ...
Newsable Asianet News on MSN
AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know
AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its ...
AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results